Study Summary
Despite the consequent use of Tocilizumab together with conventional antipyretics at early/first signs of emerging CRS, CRS (and eventually the subsequent development of ICANS) remain a major concern for patients. This study aims to identify safety and efficacy of prophylactic Tocilizumab treatment. In particular, to explore whether prophylactic Tocilizumab treatment can decrease the incidence and severity of CRS (and subsequent eventual neurotoxicity) following CAR-T-treatment.
Want to learn more about this trial?
Request More InfoInterventions
Tocilizumab before CAR-T cell infusionDRUG
Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, with completion of the infusion 1 hour prior to infusion of CAR-T cells.
Treatment of eventual subsequent CRS/ICANS will be identical as in patients in the standard arm.
Tocilizumab at emerging CRSDRUG
Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, and it will be repeated after 8 hours for a maximum of four administrations in patients with ongoing signs of CRS.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Insel Gruppe AG | Bern | Canton of Bern | Switzerland |